Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Meta-regression analysis of the association between change in six minute walk distance and survival in transthyretin-mediated amyloidosis with cardiomyopathy

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

ATTR Management Guidelines

This deck highlights published guidelines on diagnosis, treatment and disease management of ATTR.

Insights from the HELIOS-A Study

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

Musculoskeletal Manifestations Associated with ATTR Amyloidosis

This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

NfL as a Potential Biomarker in hATTR Amyloidosis

This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.

DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis

ATTR Amyloidosis Disease State Handout

This handout provides an overview of ATTR amyloidosis manifestations and the diagnostic tools that can be used to assess their presentation.

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN

This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.